Share Email Print
cover

Proceedings Paper

Fluorescent capillary fill device: a quantitative whole-blood assay system suited to point-of-care use
Author(s): Phelim B. Daniels; J. Philip Vessey; Janys E. Fletcher; Paul M. O'Neill; Christopher G. Stafford; Anthony Cope; Timothy Bacarese-Hamilton; Alan D. Cookson
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

The Fluorescence Capillary Fill Device (FCFD) has previously been shown to be a candidate test vehicle for the point of care market and instrumentation suitable for commercialization has now been developed. The FCFD instrumentation is a fluorimeter with custom optics to collect a given angular spread of light from the output edge of the device. Rigorous selection of fluorophore, light source, filters and detector (taking into account cost, availability in manufacturing quantity and the influence of inherent blood fluorescence) was undertaken when optimizing the system. The instrument utilizes allophycocyanin as a near-red fluorophore, an array of ultra-bright light emitting diodes and an inexpensive photomultiplier. Assay calibration is achieved by incorporating a light source movement mechanism that allows reference zones within the device to be interrogated individually. The resulting instrument has a footprint approximately 10 inches by 8 inches, requires no specialist operator training and is well suited to the point of care market. The capability of the system is illustrated by a whole blood assay for the cancer marker prostate specific antigen. This assay has a sensitivity of <0.5 ng/mL and precision of < 10% between 5 ng/mL and 50 ng/mL.

Paper Details

Date Published: 10 April 1998
PDF: 12 pages
Proc. SPIE 3259, Systems and Technologies for Clinical Diagnostics and Drug Discovery, (10 April 1998); doi: 10.1117/12.307336
Show Author Affiliations
Phelim B. Daniels, Quantimmune Systems Ltd. (United Kingdom)
J. Philip Vessey, Chelsea Instruments Ltd. (United Kingdom)
Janys E. Fletcher, Quantimmune Systems Ltd. (United Kingdom)
Paul M. O'Neill, Quantimmune Systems Ltd. (United Kingdom)
Christopher G. Stafford, Quantimmune Systems Ltd. (United Kingdom)
Anthony Cope, Quantimmune Systems Ltd. (United Kingdom)
Timothy Bacarese-Hamilton, Quantimmune Systems Ltd. (United Kingdom)
Alan D. Cookson, Quantimmune Systems Ltd. (United Kingdom)


Published in SPIE Proceedings Vol. 3259:
Systems and Technologies for Clinical Diagnostics and Drug Discovery
Gerald E. Cohn; John C. Owicki, Editor(s)

© SPIE. Terms of Use
Back to Top